Skip to main content
SpringerLink
Log in

Docetaxel (Taxotere®): Aktueller Stand der klinischen Entwicklung beim nichtkleinzelligen Bronchialkarzinom (NSCLC)

Docetaxel (Taxotere®): Current clinical development in non-small cell lung cancer (NSCLC)

  • Übersicht
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Zusammenfassung

□Hintergrund: Docetaxel (Taxotere®) als „stabilizing antitubulin“ gehört inzwischen zu den wirksamsten Zytostatika in der Therapie des nichtkleinzelligen Bronchialkarzinoms (NSCLC). Es wird seit geraumer Zeit bei diesem Tumor — vorrangig in klinischen Studien — in der Mono- sowie Kombinationstherapie eingesetzt und mit verschiedenen Behandlungsplänen bei lokal begrenzten Erkrankungen und im Stadium der Metastasierung geprüft.

□Studienergebnisse: Die klinische Entwicklung von Docetaxel beim NSCLC hält an und konzentriert sich aktuell auf mehrarmige, randomisierte Studien, neue Kombinationschemotherapien, den gleichzeitigen Einsatz mit der Strahlentherapie sowie die Prüfung innerhalb multimodaler Behandlungskonzepte. Die vorläufigen Ergebnisse dieser Studien bestätigen den hohen Stellenwert von Docetaxel beim NSCLC und ergänzen die bisher positiven Erfahrungen mit der Docetaxel-Mono- und -Kombinationschemotherapie.

Abstract

□Background: Docetaxel (Taxotere®) as a “stabilizing antitubulin” has in the last few years gained the reputation of being one of the most effective cytotoxic drugs in the therapy of NSCLC. Up until now it has primarily been used in clinical studies for both single agent- and combination chemotherapy being tested in a variety of different treatment regimens not only for advanced disease but also for early stage NSCLC.

□Results of Studies: Clinical investigations of Docetaxel in NSCLC continue and currently focus upon randomized studies, new combination chemotherapy regimens, its simultaneous use in combination with radiotherapy as well as trials within multi-modality treatment concepts. The preliminary results of these studies underline the importance of Docetaxel for NSCLC and confirm the positive results stemming from previous single agent- and combination therapy investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aamdal S, Hallén MN, Tonelli D, et al. Docetaxel (Taxotere,) combined with radiation in locally advanced non-small cell lung cancer (NSCLC) — a phase I/II study. Proc ASCO 1998;17:476a:1830.

    Google Scholar 

  2. Androulakis N, Kourousis C, Kakolyris S, et al. First line treatment of advanced non-small cell lung cancer with docetaxel and cis-platin: A multicenter phase II study. Eur J Cancer 1997;33:Suppl 8:236.

    Google Scholar 

  3. Belani CP, Bonomi P, Dobbs T, et al. Multicenter phase II trial of Docetaxel and Cisplatin combination in patients with non-small cell lung cancer. Proc ASCO 1997;16:462a:1660.

    Google Scholar 

  4. Belani CP, Hadeed V, Ramanathan R, et al. Docetaxel and Carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies. Proc ASCO 1997;16:220.

    Google Scholar 

  5. Belani CP. A review of Taxotere, (Docetaxel) in combination with platinum based regimens: Resent results and future developments. Oral communication Taxotere NSCLC investigators’ meeting, Los Angeles, May 1998, RPR data on file.

  6. Burris H, Eckardt J, Fields S, et al. Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc ASCO 1993;12:335–1116.

    Google Scholar 

  7. Capozzoli MJ, Belani CP, Einzig A, et al. Multi-institutional phase II trial of Docetaxel and Carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer. Proc ASCO 1998;17:1845.

    Google Scholar 

  8. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere,) is active in non-small cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994;70:384–7.

    PubMed  CAS  Google Scholar 

  9. Eole JT, Gralla RJ, Marques CB, et al. Phase I–II study of Cisplatin + Docetaxel (Taxotere,) in non-small cell lung cancer (NSCLC). Proc ASCO 1995;14:357:1087

    Google Scholar 

  10. Davis TH, Rigas JR, Maurer LH, et al. Unique two week schedule of Docetaxel and short infusion Gemcitabine for advanced solid tumors: preliminary results of a phase I trial. Proc ASCO 1998;17:239a:916.

    Google Scholar 

  11. Early E, Miller VA, Grant SC, et al. Phase I/II trial of Docetaxel and Vinorelbine with Filgrastim (G-CSF) in patients with advanced non-small cell lung cancer. Proc ASCO 1997;16:467a:1678.

    Google Scholar 

  12. Eckardt JR, Schmidt AM, Needles BM, et al. A phase I study of the combination of Docetaxel and Gemcitabine. Proc ASCO 1998;17:240a:920.

    Google Scholar 

  13. Faderl B, Pawel JV, Krauß C, et al. Phase II study of Docetaxel (D) and Cisplatin (CISPT) in a circadian timing as first line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC). Proc ASCO 1998;17:1856.

    Google Scholar 

  14. Fossella F, Devore R, Kerr R, et al. Randomized phase III study of Taxotere, (T) (100 mg/m2 and 75 mg/m2) versus Vinorelbine (V) or Ifosfamide (I) in non-small cell lung cancer (NSCLC) patients, previously treated with platinum-based chemotherapy. Proc ASCO 1998;17:1859.

    Google Scholar 

  15. Fossella FV, Lee JS, Kau SW, et al. Docetaxel for Platinum-refractory non-small cell lung cancer: comparison of phase II results to historical controls. Proc ASCO 1997;16: 468a:1682.

    Google Scholar 

  16. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of Docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 1994;12:1238–44.

    PubMed  CAS  Google Scholar 

  17. Fossella FV, Lee JS, Shin DM, et al. Phase II-study of Docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995;13:645–51.

    PubMed  CAS  Google Scholar 

  18. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of Docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994;12:1232–7.

    PubMed  CAS  Google Scholar 

  19. Gallardo D, Corona J, Martinez L, et al. Phase II trial of Docetaxel in previously untreated advanced non-small cell lung cancer. Proc 5th Int. Congr. on Anti-Cancer Chemotherapy, xxx, 1995:221.

    Google Scholar 

  20. Gandara DR, Vokes E, Green M, et al. Docetaxel (Taxotere,) in platinum-treated non-small cell lung cancer: confirmation of prolonged survival in a multicenter trial. Proc ASCO 1997;16:454a:1632.

    Google Scholar 

  21. Garland LL, Wagner H, Shaw GS, et al. Phase I dose-escalation study of constant rate infusion Gemcitabine in combination with Taxotere, in advanced non-small cell lung cancer. Proc ASCO 1998;17:1864.

    Google Scholar 

  22. Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small cell lung cancer (NSCLC) with Docetaxel (D) and Gemcitabine (G): a multicenter phase II trial. Proc ASCO 1998;17:1819.

    Google Scholar 

  23. Giannakakis T, Papadouris S Ziras N, et al. Phase I/II study of Docetaxel (D) and Carboplatin (CBDCA) as 1st line chemotherapy in advanced non-small cell lung cancer (NSCLC). Preliminary results. Proc ASCO 1998;17:1870.

    Google Scholar 

  24. Goh BC, Wang TL, Wong J, et al. Phase II trial of Docetaxel (Taxotere,) in inoperable stage III non-small cell lung cancer. Proc ASCO 1997;16:469a:1686.

    Google Scholar 

  25. Griesinger F, Kern W, Binder L, et al. Outpatient Taxotere,/Carboplatin (T/C) combination therapy in NSCLC for induction in stage IIIB and palliation in stage IV. Proc ASCO 1998;17:1874.

    Google Scholar 

  26. Kourousis C, Kakolyris S, Androullakis N, et al. First line treatment on non-small cell lung carcinoma with Docetaxel and Vinorelbine: a phase II study. Proc ASCO 1996;15:405:1234.

    Google Scholar 

  27. Kris MG, moderator. Docetaxel: emerging options in the management of non-small cell lung cancer. Oncology 1997;11:Suppl 7:9–40.

    Google Scholar 

  28. LeChevalier T, Belli L, Monnier A, et al. Phase II study of Docetaxel (Taxotere,) and Cisplatin in advanced non-small cell lung cancer (NSCLC): an interim analysis. Proc ASCO 1995;14:350:1056.

    Google Scholar 

  29. Lira-Puerto V, Zepeda G, Mohar A, et al. Phase II trial of Taxotere (Docetaxel) in advanced non-small cell lung cancer. Proc ASCO 1995;14:382:1186.

    Google Scholar 

  30. Löffler TM. Personal communication 1998.

  31. Lück HJ, Donnè S, Glaubitz M, et al. Phase I study of weekly docetaxel (Taxotere,) in heavily pretreated breast cancer patients. Eur J Cancer 1997;33:Suppl 8:158.

    Google Scholar 

  32. Manegold C. Docetaxel (Taxotere,) beim nichtkleinzelligen Bronchialkarzinom. Med Klin 1997;92:Suppl IX:10–5.

    Article  CAS  Google Scholar 

  33. Masters GA, Melton K, Brockstein BE, et al. A dose escalation study of Docetaxel with G-CSF in patients with advanced solid tumors: a phase I trial. Proc ASCO 1998;17:248a:950.

    Google Scholar 

  34. Mattson K, Ten Velde G, Krofta K, et al. Taxotere, as neoadjuvant therapy for radically-treatable stage III NSCLC. Preliminary results of an international phase III study. Proc ASCO 1998;17:1904.

    Google Scholar 

  35. Mattson K, Vansteenkiste J, Saarinen A, et al. Phase II study of Docetaxel alternating with Cisplatin for advanced NSCLC preliminary report of European multicenter trial. Proc ASCO 1997;16:474a:1707.

    Google Scholar 

  36. Mattson K. Taxotere, (Docetaxel): Neoadjuvant chemotherapy for NSCLC. Oral communication Taxotere NSCLC investigators’ meeting, Los Angeles, May 1998, RPR data on file.

  37. Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of Docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16:159–64.

    PubMed  CAS  Google Scholar 

  38. Miller VA, Grant SC, Ng K, et al. Phase I trial of Docetaxel (DTX) and Vinorelbine (VNR) with Filgrastim in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 1998;17:471a:1813.

    Google Scholar 

  39. Miller VA, Rigas JR, Francis PA, et al. Phase II-trial of a 75-mg/m2 dose of Docetaxel with Prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968–72.

    Article  PubMed  CAS  Google Scholar 

  40. Monnier A, Riviere A, Douillard JY, et al. Phase II study of Docetaxel (Taxotere,) and Vinorelbine in chemotherapy naive patients with advanced non-small cell lung carcinoma (NSCLC). Proc ASCO 1996;15:378:1129.

    Google Scholar 

  41. Orcel B, Antoine EC, Benhammouda A, et al. Sequential administration of Docetaxel followed by Cisplatin-Vindesine in chemotherapy naive patients with locally advanced or metastatic non-small cell lung cancer: preliminary report. Proc ASCO 1997;16:477a:1718.

    Google Scholar 

  42. Pawinski A, Louwerens M, Tonelli D, et al. A phase I study of Taxotere, and Gemzar, in patients with advanced solid tumors. Proc ASCO 1998;17:249a:957.

    Google Scholar 

  43. Peacock NW, Burris HA, Hainsworth JD, et al. Weekly docetaxel in patients with advanced refractory malignancies: a phase I trial. Proc ASCO 1998;17:189a:727.

    Google Scholar 

  44. Rebattu P, Puljol JL, Ardiet C, et al. Combination of docetaxel (DTX) and gemcitabine (G) in patients with inoperable or metastatic non-small cell lung cancer (NSCLC). A phase I study. Preliminary results on active regimen. Ann Oncol 1998;9:Suppl 2:95.

    Google Scholar 

  45. Robinet G, Kleisbauer JP, Thomas P, et al. Phase II study of Docetaxel (Taxotere,) in first- and second-line NSCLC. Proc ASCO 1997;16:480a:1726.

    Google Scholar 

  46. Schiller JH, Larson M, Larson M, et al. Phase I trial of Docetaxel and Vinorelbine in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Proc ASCO 1997;16:481a:1733.

    Google Scholar 

  47. Schlösser NJJ, Richel DJ, van Sandwijk N, et al.: Phase I study of Docetaxel and Gemcitabine combination chemotherapy in chemotherapy naive patients with advanced or metastatic non-small cell lung cancer. Proc ASCO 1998;17:1924.

    Google Scholar 

  48. Smythe JF, Kris MG, eds. The development of Docetaxel (Taxotere,) in non-small cell lung cancer Semin Oncol 1997;24:Suppl 14:1–32.

    Google Scholar 

  49. Spiridonidis CH, Laufman LR, Jones JJ, et al. Weekly Gemcitabine combined with monthly Docetaxel in patients with advanced malignancies: a phase I trial. Proc ASCO 1998;17:2068a:795.

    Google Scholar 

  50. Teng M, Choy H, DeVore RD, et al. Phase I trial of outpatient weekly Docetaxel and concurrent radiation therapy for stage III unresectable non-small cell lung cancer: a vanderbilt cancer center affiliate network (VCCAN) trial. Proc ASCO 1998;17:503a:1938.

    Google Scholar 

  51. van Oosterom AT. Docetaxel and Gemcitabine: Results and overview of angoing studies. Oral communication Taxotere NSCLC investigators’ meeting. Los Angeles, May 1998, RPR data file.

  52. Viallet J, Laberge F, Martins H, et al. Docetaxel alternating with Cisplatin and Vinorelbine: Early evidence of additive activity in a phase II trial of non-small cell lung cancer (NSCLC). Proc ASCO 1996;15:375:1115.

    Google Scholar 

  53. Watanabe K, Hayashi I, Hiraki S, et al. Phase I/II dose escalation study of Docetaxel and Cisplatin for stage IV non-small cell lung cancer. Proc ASCO 1997;16:254a:899.

    Google Scholar 

  54. Watanabe K, Yokoyama A, Furuse K, et al. Phase II trial of Docetaxel in previously untreated non-small cell lung cancer (NSCLC). Proc ASCO 1994;13:331:1095.

    Google Scholar 

  55. Zalcberg JR, Bishop JF, Millward MJ, et al. Preliminary results of the first phase II trial of Docetaxel in combination with Cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Proc ASCO 1995;14:351:1062.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thoraxklinik der LVA, Amalienstaße 5, D-69126, Heidelberg

    Christian Manegold

Authors
  1. Christian Manegold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Manegold.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manegold, C. Docetaxel (Taxotere®): Aktueller Stand der klinischen Entwicklung beim nichtkleinzelligen Bronchialkarzinom (NSCLC). Med Klin 93 (Suppl 3), 16–21 (1998). https://doi.org/10.1007/BF03042003

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03042003

Schlüsselwörter

Key Words

Search

Navigation